Predicting the Toxicity of Adjuvant Breast Cancer Drug Combination Therapy

2013 ◽  
Author(s):  
Susan F. Hudachek
Keyword(s):  
Breast Cancer ◽  
Combination Therapy ◽  
Drug Combination ◽  
Cancer Drug ◽  
Drug Combination Therapy ◽  
Adjuvant Breast Cancer

Rational drug combination therapy for improved efficacy and delayed resistance in triple negative breast cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13113-e13113
Author(s):  
Rabia Gilani ◽  
Eric Lachacz ◽  
Li Wei Bao ◽  
Sameer Phadke ◽  
Matthew Soellner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Combination Therapy ◽  
Triple Negative Breast Cancer ◽  
Drug Combination ◽  
Triple Negative ◽  
Drug Combination Therapy ◽  
Rational Drug

scholarly journals Drug combination therapy increases successful drug repositioning

2016 ◽  
Vol 21 (7) ◽  
pp. 1189-1195 ◽  
Author(s):  
Wei Sun ◽  
Philip E. Sanderson ◽  
Wei Zheng
Keyword(s):  
Combination Therapy ◽  
Drug Combination ◽  
Drug Repositioning ◽  
Drug Combination Therapy

Differential tissue distribution of discrete typing units after drug combination therapy in experimental Trypanosoma cruzi mixed infection

Parasitology ◽  
2021 ◽  
pp. 1-29
Author(s):  
Mariana Strauss ◽  
M. Silvina Lo Presti ◽  
Juan C. Ramírez ◽  
P. Carolina Bazán ◽  
Daniela A. Velázquez López ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Trypanosoma Cruzi ◽  
Tissue Distribution ◽  
Mixed Infection ◽  
Drug Combination ◽  
Drug Combination Therapy ◽  
Differential Tissue

scholarly journals Molecular Simulations Identify Target Receptor Kinases Bound by Astaxanthin to Induce Breast Cancer Cell Apoptosis

2020 ◽  
pp. 72-82
Author(s):  
Mossa Gardaneh ◽  
Zahra Nayeri ◽  
Parvin Akbari ◽  
Mahsa Gardaneh ◽  
Hasan Tahermansouri
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Combination Therapy ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Molecular Mechanisms ◽  
Cancer Cell Lines ◽  
Cancer Drug ◽  
Breast Cancer Cell Lines

Background: We investigated molecular mechanisms behind astaxanthinmediated induction of apoptosis in breast cancer cell lines toward combination therapy against cancer drug resistance. Methods: Breast cancer cell lines were treated with serial concentrations of astaxanthin to determine its IC50. We used drug-design software to predict interactions between astaxanthin and receptor tyrosine kinases or other key gene products involved in intracellular signaling pathways. Changes in gene expression were examined using RT-PCR. The effect of astaxanthin-nanocarbons combinations on cancer cells was also evaluated. Results: Astaxanthin induced cell death in all three breast cancer cell lines was examined so that its IC50 in two HER2-amplifying lines SKBR3 and BT-474 stood, respectively, at 36 and 37 ?M; however, this figure for MCF-7 was significantly lowered to 23 ?M (P<0.05). Astaxanthin-treated SKBR3 cells showed apoptotic death upon co-staining. Our in silico examinations showed that some growth-promoting molecules are strongly bound by astaxanthin via their specific amino acid residues with their binding energy standing below -6 KCa/Mol. Next, astaxanthin was combined with either graphene oxide or carboxylated multi-walled carbon nanotube, with the latter affecting SKBR cell survival more extensively than the former (P<0.05). Finally, astaxanthin coinduced tumor suppressors p53 and PTEN but downregulated the expression of growth-inducing genes in treated cells. Conclusion: These findings indicate astaxanthin carries' multitarget antitumorigenic capacities and introduce the compound as a suitable candidate for combination therapy regimens against cancer growth and drug resistance. Development of animal models to elucidate interactions between the compound and tumor microenvironment could be a major step forward towards the inclusion of astaxanthin in cancer therapy trials.

scholarly journals A COMPARATIVE EVALUATION OF THE EFFICACY OF TRIPLE DRUG THERAPY WITH DUAL DRUG THERAPY IN COPD PATIENTS

2018 ◽  
Vol 10 (4) ◽  
pp. 105
Author(s):  
Pathan Amanulla Khan ◽  
A. Sujala ◽  
B.b. Sarah Nousheen ◽  
Ayesha Farhath Fatima ◽  
Hibba Tul Ala ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Combination Therapy ◽  
Triple Therapy ◽  
Drug Combination ◽  
Dual Therapy ◽  
Drug Combination Therapy ◽  
Copd Patients ◽  
Number Of Patients ◽  
Dual Drug

Objective: The present study was conducted with the objective of analyzing the efficacy of triple-drug combination therapy (formoterol, ciclesonide, tiotropium) by comparing it with double drug combination therapy (formoterol, budesonide).Methods: A prospective observational study was conducted. Sixty patients were enrolled, and divided into two groups of thirty each; one group was treated with the double-drug and the other with a triple drug combination. FEV1 and FVC pre-and post-treatment in either group were assessed spirometrically. Score ranges of 0-10, 11-20 and 21-30 were allotted to mild, moderate and severe categories and results were analyzed statistically.Results: Of the 60 patients recruited, 61-70 y olds constituted the majority (35%) of the population. Males (63.3%) were more in number compared to females (36.6%). Twenty-three of thirty-eight men smoked (60.5%); there were no female smokers. Common symptoms included cough (93.3%), dyspnoea (85%), fever (45%) and haemoptysis (15%). Hypertension accounted for 70% of patient comorbidities, followed by diabetes (60%) and cardiovascular diseases (40%). Three months after treatment with triple therapy, a significant increase in the differences of means of both FEV1 (14.27) and FVC (14.90) values was observed. Further analysis based on score ranges demonstrated that triple therapy administration markedly reduced the number of patients suffering from severe COPD.Conclusion: Our comparative analysis indicated that triple therapy was more effective in improving lung function, enhancing patients’ quality of life (evidenced from score ranges) thereby reducing mortality. While much is known about the greater effectiveness of triple over dual therapy, researchers to formulate the most effective triple therapy are in progress.

Sign in / Sign up

Export Citation Format

Share Document